Optimization of Rosiglitazone synthesis in batch and flow processes in microreactors

• Grant number: 18/19294-8
• Support type: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): November 01, 2018
• Effective date (End): October 31, 2019
• Field of knowledge: Engineering - Chemical Engineering
• Principal Investigator: Mauri Sergio Alves Palma
• Grantee: Caroline Araskiro Pessoa
• Home Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

The increase in cases of diabetes mellitus type 2 in Brazil in the last decade encourages the search for new drugs to fight it. There are more than 400 million people affected by that disease around the world. The illness is characterized especially by the excess of glucose in the blood and irregular secretion of insulin. Rosiglitazone (Avandia ®), was the first drug from the glitazone class commercialized and that works like insulin sensitizer in humans. The technology of microreactors aimed at the intensification of processes and is important in the search for equipment and less hazardous and safe reactions. The pharmaceutical industry is the largest beneficiary of this technology because the microreactors can reduce in years the time to develop and produce a new drug, and can be built in extremely small and compact industrial units with better process control. In this work, the application of capillary microreactors will be tested for 2 out of 5 reactions of Rosiglitazone synthesis in the batch process and its transposition for the flow process in a microreactor. This work will be developed in the scope of a research project financed by Fapesp grant number 2017/12830-9 entitled "Synthesis of Pioglitazone, Rosiglitazone, and Lobeglitazone in a continuous flow in capillary microreactors" active from 10/1/2017 to 09/30/2019.